Clinical Studies with MTA
Author Information
Author(s): AH Calvert, JM Walling
Primary Institution: Division of Oncology, Newcastle General Hospital
Hypothesis
It is not known whether the anti-tumour activity of MTA depends on its TS inhibition or whether other loci contribute.
Conclusion
MTA appears to show promising activity in the treatment of several solid tumours, including breast, colorectal, pancreas, and NSCL cancers.
Supporting Evidence
- MTA has been shown to have activity against a range of human cell lines, including colon, renal, hepatoma, and lung cancer.
- Preliminary phase II trials results are encouraging; responses were seen in colorectal, pancreas, NSCLC, and breast cancer.
- Phase II trials are being carried out in patients with solid tumours, particularly cancers of the breast and pancreas.
Takeaway
MTA is a new medicine that helps fight cancer by blocking certain enzymes, and it seems to work well for different types of cancer.
Methodology
MTA was examined in three phase I trials using different schedules: a 10-min i.v. infusion given once every 3 weeks, once weekly for 4 weeks every 6 weeks, or daily for 5 days every 3 weeks.
Limitations
The phase II results are preliminary and further data are required before conclusions can be drawn regarding the absolute efficacy.
Participant Demographics
{"male":27,"female":10,"age_range":"30-74","median_age":59}
Want to read the original?
Access the complete publication on the publisher's website